| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 03/24/2011 | US20110071222 Potentiators of insulin secretion |
| 03/24/2011 | US20110071221 Method for treating conditions mediated by ppar using macelignan |
| 03/24/2011 | US20110071198 Nicotinic acid receptor ligands |
| 03/24/2011 | US20110071195 Novel alkene oxindole derivatives |
| 03/24/2011 | US20110071184 Manufacture of tablet in a die utilizing radiofrequency energy and meltable binder |
| 03/24/2011 | US20110071179 Macrocyclic inhibitors of jak |
| 03/24/2011 | US20110071178 Methods and Compounds for Modulating Cannabinoid Activity |
| 03/24/2011 | US20110071176 Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| 03/24/2011 | US20110071166 Medicine consisting of concomitant use or combination of dpp-iv inhibitor and other diabetic medicine |
| 03/24/2011 | US20110071162 Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof |
| 03/24/2011 | US20110071161 Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof |
| 03/24/2011 | US20110071160 1,3-DIHYDRO-2H-PYRROLO[3,2-b]PYRIDIN-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF |
| 03/24/2011 | US20110071159 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ' ] -bipyridine and its use as a medicament |
| 03/24/2011 | US20110071149 Selective kinase inhibitors |
| 03/24/2011 | US20110071148 Compounds as the estrogen related receptors modulators and the uses thereof |
| 03/24/2011 | US20110071144 Quinazoline derivatives and pharmaceutical compositions containing them |
| 03/24/2011 | US20110071143 Fused triazole amines as p2x7 modulators |
| 03/24/2011 | US20110071139 Cycloalkyl Lactame Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 |
| 03/24/2011 | US20110071129 Spirodiamine-diaryl ketoxime derivative |
| 03/24/2011 | US20110071111 Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome |
| 03/24/2011 | US20110071110 Water Dispersible Policosanol Cyclodextrin Complex and Method of its Production |
| 03/24/2011 | US20110071109 Histone deacetylase inhibitors as therapeutic agents for lysosomal storage disorders |
| 03/24/2011 | US20110071107 Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome |
| 03/24/2011 | US20110071082 Long lasting anti-angiogenic peptides |
| 03/24/2011 | US20110071081 Methods useful in the treatment of bone resorption diseases |
| 03/24/2011 | US20110071076 Novel exendin agonist compounds |
| 03/24/2011 | US20110071075 Promoter for bicarbonate secretion in gastrointestinal tract |
| 03/24/2011 | US20110070319 Bifeprunox doses for treating schizophrenia |
| 03/24/2011 | US20110070297 Glucokinase activators |
| 03/24/2011 | US20110070296 Topical compositions and methods for utilizing peptides containing lipid-modified cysteine-containing peptides |
| 03/24/2011 | US20110070291 Food or beverage composition fortified with thyronamines and/or thyronamine precursors |
| 03/24/2011 | US20110070289 Adaptable modified virus vector to deliver modified messenger ribonucleic acid as a medical treatment device to manage diabetes mellitus and other protein deficient diseases |
| 03/24/2011 | US20110070272 Materials and Methods for Modulating Metabolism |
| 03/24/2011 | US20110070258 Method of slowing the aging process by activating sirtuin enzymes |
| 03/24/2011 | US20110070242 Methods for Diagnosing and Treating Iron Dysregulation |
| 03/24/2011 | US20110070237 Methods of modulating and identifying agents that modulate intracellular calcium |
| 03/24/2011 | US20110070224 Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue |
| 03/24/2011 | US20110070223 Uses of Lp-PLA2 in combination to assess coronary risk |
| 03/24/2011 | US20110070205 Multipotent stem cells and uses thereof |
| 03/24/2011 | US20110070201 Mucosal or enteral administration of biologically active macromolecules |
| 03/24/2011 | US20110070192 Method of preparation of novel nucleoside analogs and uses |
| 03/24/2011 | CA2774327A1 Pharmaceutical compositions which inhibit fkbp52-mediated regulation of androgen receptor function and methods of using same |
| 03/24/2011 | CA2774313A1 A plant extract, compositons containing same, a method of extraction and uses thereof |
| 03/24/2011 | CA2774239A1 Treatment for oxidative stress and/or hypertension |
| 03/24/2011 | CA2774073A1 Anti-obesity agent, anti-obesity food or beverage, glucose tolerance-ameliorating agent, and food or beverage for amelioration of glucose tolerance |
| 03/24/2011 | CA2773125A1 Compounds having tafia inhibitory activity |
| 03/24/2011 | CA2772689A1 Glycine compound |
| 03/24/2011 | CA2772674A1 Alkene oxindole derivatives and their uses to treat obesity, diabetes and hyperlipidemia |
| 03/24/2011 | CA2772504A1 (4-phenyl-piperidin-1-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds and their use |
| 03/24/2011 | CA2772105A1 Fused triazole amines as p2x7 modulators |
| 03/23/2011 | EP2298803A2 Human G-protein coupled receptor and ligands thereof |
| 03/23/2011 | EP2298801A1 Glycosylated glp-1 peptide |
| 03/23/2011 | EP2298779A1 Sulfonamide derivatives as glycokinase activators useful in the treatment of type 2 diabetes |
| 03/23/2011 | EP2298769A1 Xanthin derivatives, their production and utilisation as medicine |
| 03/23/2011 | EP2298752A1 Alpha-form or beta-form crystal of acetanilide derivative |
| 03/23/2011 | EP2298750A1 Novel isoxazole derivative |
| 03/23/2011 | EP2298747A1 Triazole derivative or salt thereof |
| 03/23/2011 | EP2298742A1 Phenoxy acetic acids as PPAR delta activators |
| 03/23/2011 | EP2298357A1 Compositions and methods for regulated protein expression in gut |
| 03/23/2011 | EP2298355A2 Albumin fusion proteins |
| 03/23/2011 | EP2298354A2 Remodelling and glycoconjugation of interferon-beta |
| 03/23/2011 | EP2298348A1 Antibody binding alpha4Beta7 integrin and its use to treat inflammatory bowel disease |
| 03/23/2011 | EP2298337A2 Regulation of food preference using GLP-1 agonists |
| 03/23/2011 | EP2298331A2 Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
| 03/23/2011 | EP2298320A1 Use of lanostane and poria extract in treating diabetes |
| 03/23/2011 | EP2298301A2 Medicaments for increasing endogenous Erythropoietin (EPO) |
| 03/23/2011 | EP2298293A1 Lipase inhibitor |
| 03/23/2011 | EP2298284A2 Mucoadhesive pharmaceutical formulations |
| 03/23/2011 | EP2298283A2 Pharmaceutical formulations comprising cannabinoids |
| 03/23/2011 | EP2298282A1 Combination of drugs having different physical properties into single dosage form |
| 03/23/2011 | EP2297166A1 Substituted n-imidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-ht6 ligands |
| 03/23/2011 | EP2297164A1 Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| 03/23/2011 | EP2297163A1 Pyrazolospiroketone acetyl-c0a carboxylase inhibitors |
| 03/23/2011 | EP2297144A1 Imidazopyridine and related analogs as sirtuin modulators |
| 03/23/2011 | EP2297131A2 Di-substituted phenyl compounds as phosphodiesterase 10 inhibitors |
| 03/23/2011 | EP2297129A1 Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
| 03/23/2011 | EP2297117A1 Bicyclic heterocycle derivatives and use thereof as gpr119 modulators |
| 03/23/2011 | EP2296709A2 Modified release niacin formulations |
| 03/23/2011 | EP2185567B1 Substituted bicyclolactam compounds |
| 03/23/2011 | EP2102214B1 4, 5, 6, 7-tetrahydro-thieno [3, 2-c] pyridine derivatives as h3 modulators |
| 03/23/2011 | EP1881960B1 Novel specific caspase-10 inhibitors |
| 03/23/2011 | EP1515741B1 Use of collagen hydrolysate to lower the viscosity of a composition comprising guar gum |
| 03/23/2011 | EP1448205B1 Combinations for the treatment of immunoinflammatory disorders |
| 03/23/2011 | EP1351707B1 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays |
| 03/23/2011 | EP1278748B1 Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 03/23/2011 | CN1951372B Solid oral dosage forms comprising valsartan and HCTZ |
| 03/23/2011 | CN1931233B Medicine composition of red sage and epimedium for treating cardiac and cerebral vascular diseases |
| 03/23/2011 | CN1929824B Soft gelatin capsule comprising omega-3-polyunsaturated fatty acid |
| 03/23/2011 | CN1923228B Pharmaceutical composition comprising notoginseng extract, Danshen extract and ligustrazine |
| 03/23/2011 | CN1717268B Nutraceutical compositions comprising epigallocatechin gallate and raspberry ketone |
| 03/23/2011 | CN101990541A Fused heteroaryl modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof |
| 03/23/2011 | CN101990535A Benzofurane, benzothiophene, benzothiazol derivatives as fxr modulators |
| 03/23/2011 | CN101990431A Methods and assays for detecting and treating hypoglycemia |
| 03/23/2011 | CN101987868A Derivative or pharmaceutically acceptable salt of GLP-1 analogue and application of derivative or pharmaceutically-acceptable salt of a GLP-1 analogue |
| 03/23/2011 | CN101987813A Chemical total synthesis method for type II anti-diabetic medicament hypnopyrine |
| 03/23/2011 | CN101987188A Biological Chinese patent drug for preventing and treating hyperlipoidemia |
| 03/23/2011 | CN101987184A Traditional Chinese medicine for treating diabetes mellitus limb necrosis |
| 03/23/2011 | CN101987179A Red yeast rice generated component composite capable of resisting body fat formation and preparation method thereof |
| 03/23/2011 | CN101987175A Traditional Chinese medicine for treating diabetic gastroplegia |
| 03/23/2011 | CN101987174A Traditional Chinese medicine for treating diabetic peripheral neuropathy |